427 related articles for article (PubMed ID: 33646447)
1. Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study.
Hsu HC; Chang YS; Hou TY; Chen LF; Hu LF; Lin TM; Chiou CS; Tsai KL; Lin SH; Kuo PI; Chen WS; Lin YC; Chen JH; Chang CC
Clin Rheumatol; 2021 Sep; 40(9):3755-3763. PubMed ID: 33646447
[TBL] [Abstract][Full Text] [Related]
2. Pneumocystis Jirovecii Pneumonia in Systemic Lupus Erythematosus: A Nationwide Cohort Study in Taiwan.
Wang WH; Lai CC; Huang YF; Li TH; Tsao YP; Chen WS; Chang YS
Arthritis Care Res (Hoboken); 2022 Sep; 74(9):1444-1450. PubMed ID: 33645012
[TBL] [Abstract][Full Text] [Related]
3. Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: A case-control study.
Tadros S; Teichtahl AJ; Ciciriello S; Wicks IP
Semin Arthritis Rheum; 2017 Jun; 46(6):804-809. PubMed ID: 27814896
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics of and risk factors for Pneumocystis jirovecii pneumonia in anti-melanoma differentiation-associated gene 5 (Anti-MDA5) antibody-positive dermatomyositis patients: a single-center retrospective study.
Li J; Wang S; Zheng J; Li Q; Li J; Lu L
Clin Rheumatol; 2023 Feb; 42(2):453-462. PubMed ID: 36301369
[TBL] [Abstract][Full Text] [Related]
5. Rates of Pneumocystis jirovecii pneumonia and prophylaxis prescribing patterns in a large electronic health record cohort of patients with systemic lupus erythematosus.
Boone B; Lazaroff SM; Wheless L; Wolfe RM; Barnado A
Semin Arthritis Rheum; 2022 Dec; 57():152106. PubMed ID: 36279805
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology, mortality and effectiveness of prophylaxis for Pneumocystis jiroveci pneumonia among rheumatic patients: a territory-wide study.
Chan SCW; Chung HY; Lau CS; Li PH
Ann Clin Microbiol Antimicrob; 2021 Nov; 20(1):78. PubMed ID: 34763703
[TBL] [Abstract][Full Text] [Related]
7. Risk of autoimmune rheumatic diseases in patients with palindromic rheumatism: A nationwide, population-based, cohort study.
Chen HH; Chao WC; Liao TL; Lin CH; Chen DY
PLoS One; 2018; 13(7):e0201340. PubMed ID: 30048527
[TBL] [Abstract][Full Text] [Related]
8. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.
Schmajuk G; Jafri K; Evans M; Shiboski S; Gianfrancesco M; Izadi Z; Patterson SL; Aggarwal I; Sarkar U; Dudley RA; Yazdany J
Semin Arthritis Rheum; 2019 Jun; 48(6):1087-1092. PubMed ID: 30449650
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune rheumatic diseases increase dementia risk in middle-aged patients: A nationwide cohort study.
Lin TM; Chen WS; Sheu JJ; Chen YH; Chen JH; Chang CC
PLoS One; 2018; 13(1):e0186475. PubMed ID: 29304089
[TBL] [Abstract][Full Text] [Related]
10. Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality.
Song S; Zhang Y; Yu J; Xie C; Chen Y; Zhang X
BMC Infect Dis; 2022 Dec; 22(1):961. PubMed ID: 36575406
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature.
Gupta D; Zachariah A; Roppelt H; Patel AM; Gruber BL
J Clin Rheumatol; 2008 Oct; 14(5):267-72. PubMed ID: 18679133
[TBL] [Abstract][Full Text] [Related]
12. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience.
Mecoli CA; Saylor D; Gelber AC; Christopher-Stine L
Clin Exp Rheumatol; 2017; 35(4):671-673. PubMed ID: 28134084
[TBL] [Abstract][Full Text] [Related]
13. High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center.
Huang L; Fu Q; Ye Y; Lin Y; Yan Q; Chen S
Arthritis Res Ther; 2021 Sep; 23(1):232. PubMed ID: 34481528
[TBL] [Abstract][Full Text] [Related]
14. Risk of interstitial lung disease in patients with newly diagnosed systemic autoimmune rheumatic disease: A nationwide, population-based cohort study.
Ng KH; Chen DY; Lin CH; Chao WC; Chen YM; Chen YH; Huang WN; Hsieh TY; Lai KL; Tang KT; Chen HH
Semin Arthritis Rheum; 2020 Oct; 50(5):840-845. PubMed ID: 32896697
[TBL] [Abstract][Full Text] [Related]
15. Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases.
Braga BP; Prieto-González S; Hernández-Rodríguez J
Med Clin (Barc); 2019 Jun; 152(12):502-507. PubMed ID: 30853123
[TBL] [Abstract][Full Text] [Related]
16. Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study.
Hsu CY; Ko CH; Wang JL; Hsu TC; Lin CY
Arthritis Res Ther; 2019 Oct; 21(1):211. PubMed ID: 31604447
[TBL] [Abstract][Full Text] [Related]
17. Cancer Risk in Patients With Inflammatory Systemic Autoimmune Rheumatic Diseases: A Nationwide Population-Based Dynamic Cohort Study in Taiwan.
Yu KH; Kuo CF; Huang LH; Huang WK; See LC
Medicine (Baltimore); 2016 May; 95(18):e3540. PubMed ID: 27149461
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune rheumatic diseases and the risk of Parkinson disease: a nationwide population-based cohort study in Taiwan.
Chang CC; Lin TM; Chang YS; Chen WS; Sheu JJ; Chen YH; Chen JH
Ann Med; 2018 Feb; 50(1):83-90. PubMed ID: 29224375
[TBL] [Abstract][Full Text] [Related]
19.
Verhaert M; Blockmans D; De Langhe E; Henckaerts L
Scand J Rheumatol; 2020 Sep; 49(5):345-352. PubMed ID: 32662308
[No Abstract] [Full Text] [Related]
20. Cytomegaloviral or
Sun YS; Huang DF; Lin FC; Hsu CK; Sun IT; Chang SC; Tsai CY; Lai CC
J Rheumatol; 2019 Mar; 46(3):251-258. PubMed ID: 30504509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
